Abstract
The Cambridge, Massachusetts–based start-up Caraway Therapeutics has partnered with AbbVie to develop a small molecule that modulates a potassium ion channel called TMEM175 to treat Parkinson’s disease and other neurodegenerative disorders. TMEM175 is important to the function of lysosomes that break down old proteins in cells. Caraway will get $17 million up front and could earn up to $267 million in future payments. After Caraway conducts additional preclinical research, AbbVie has the option to license the program.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
